Toni H. Choueiri und Exelixis - Info zur Person

(1 - 10 von 11

)

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death...

www.reuters.com

Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated...

Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of...

www.finanznachrichten.de

- Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of...

Exelixis’ Partner Ipsen Announces European Commission Approval of...

apnews.com

These results were first presented by Dr. Toni Choueiri at the European Society for Medical Oncology (ESMO) Congress, and published ...

Exelixis and Pfizer drugs compete in kidney cancer trial - Reuters

www.reuters.com

Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to...

Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data...

www.businesswire.com

Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Session: Presidential Symposium 3, Monday, October 10, – 16:30-18:10 CEST, Copenhagen room. Note: This is a National Cancer Institute Cancer Therapy Evaluation ...

Bristol Myers Squibb and Exelixis Announce Positive ...

pipelinereview.com

“The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in the key efficacy measures of progression-free survival and overall survival for previously untreated kidney cancer patients,” said Dr. Toni Choueiri, Director of the Lank Center ...

Does cabozantinib have potential to become a first-line treatment for...

medonline.at

Dr Toni Choueiri, Director, Kidney Cancer Center, Dana-Farber Cancer Institute, Boston, US The CABOzantinib versus SUNitinib (CABOSUN) study was conducted by the Alliance for Clinical Trials in Oncology, part of Exelixis’ collaboration with the National Cancer Institute (NCI) Cancer Therapy Evaluation Program.

Exelixis Completes Enrollment of the METEOR Phase

pipelinereview.com

“METEOR was designed to evaluate cabozantinib’s potential as a treatment for metastatic renal cell carcinoma, an aggressive form of the disease that is usually incurable,” said Toni Choueiri, MD, clinical director of the Lank Center for Genitourinary Oncology and director of the kidney cancer center, Dana-Farber Cancer Institute.

Personen
Vorname "Toni" (11215)
Name "Choueiri" (39)

sortiert nach Relevanz / Datum

Erweiterte Suche

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Toni H. Choueiri und Exelixis Person-Info